Mineralys Therapeutics, Common Stock Market Value
| MLYS Stock | 12.70 0.21 1.68% |
| Symbol | Mineralys |
Mineralys Therapeutics, Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mineralys Therapeutics,. If investors know Mineralys will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mineralys Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.31) | Return On Assets (0.39) | Return On Equity (0.61) |
The market value of Mineralys Therapeutics, is measured differently than its book value, which is the value of Mineralys that is recorded on the company's balance sheet. Investors also form their own opinion of Mineralys Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Mineralys Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mineralys Therapeutics,'s market value can be influenced by many factors that don't directly affect Mineralys Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mineralys Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Mineralys Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mineralys Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Mineralys Therapeutics, 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Mineralys Therapeutics,'s stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Mineralys Therapeutics,.
| 10/27/2024 |
| 11/26/2024 |
If you would invest 0.00 in Mineralys Therapeutics, on October 27, 2024 and sell it all today you would earn a total of 0.00 from holding Mineralys Therapeutics, Common or generate 0.0% return on investment in Mineralys Therapeutics, over 30 days. Mineralys Therapeutics, is related to or competes with Eliem Therapeutics, HCW Biologics, Scpharmaceuticals, Milestone Pharmaceuticals, Seres Therapeutics, and Lumos Pharma. Mineralys Therapeutics, is entity of United States More
Mineralys Therapeutics, Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Mineralys Therapeutics,'s stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Mineralys Therapeutics, Common upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 3.63 | |||
| Information Ratio | 0.0251 | |||
| Maximum Drawdown | 20.98 | |||
| Value At Risk | (5.79) | |||
| Potential Upside | 6.27 |
Mineralys Therapeutics, Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Mineralys Therapeutics,'s investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Mineralys Therapeutics,'s standard deviation. In reality, there are many statistical measures that can use Mineralys Therapeutics, historical prices to predict the future Mineralys Therapeutics,'s volatility.| Risk Adjusted Performance | 0.0537 | |||
| Jensen Alpha | (0.08) | |||
| Total Risk Alpha | (0.38) | |||
| Sortino Ratio | 0.0262 | |||
| Treynor Ratio | 0.0881 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Mineralys Therapeutics,'s price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Mineralys Therapeutics, Backtested Returns
Currently, Mineralys Therapeutics, Common is not too volatile. Mineralys Therapeutics, has Sharpe Ratio of 0.038, which conveys that the firm had a 0.038% return per unit of risk over the last 3 months. We have found twenty-eight technical indicators for Mineralys Therapeutics,, which you can use to evaluate the volatility of the firm. Please verify Mineralys Therapeutics,'s Mean Deviation of 2.68, downside deviation of 3.63, and Risk Adjusted Performance of 0.0537 to check out if the risk estimate we provide is consistent with the expected return of 0.15%. Mineralys Therapeutics, has a performance score of 2 on a scale of 0 to 100. The company secures a Beta (Market Risk) of 2.45, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Mineralys Therapeutics, will likely underperform. Mineralys Therapeutics, right now secures a risk of 3.84%. Please verify Mineralys Therapeutics, Common value at risk, as well as the relationship between the kurtosis and price action indicator , to decide if Mineralys Therapeutics, Common will be following its current price movements.
Auto-correlation | 0.20 |
Weak predictability
Mineralys Therapeutics, Common has weak predictability. Overlapping area represents the amount of predictability between Mineralys Therapeutics, time series from 27th of October 2024 to 11th of November 2024 and 11th of November 2024 to 26th of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Mineralys Therapeutics, price movement. The serial correlation of 0.2 indicates that over 20.0% of current Mineralys Therapeutics, price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.2 | |
| Spearman Rank Test | -0.25 | |
| Residual Average | 0.0 | |
| Price Variance | 0.86 |
Mineralys Therapeutics, lagged returns against current returns
Autocorrelation, which is Mineralys Therapeutics, stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Mineralys Therapeutics,'s stock expected returns. We can calculate the autocorrelation of Mineralys Therapeutics, returns to help us make a trade decision. For example, suppose you find that Mineralys Therapeutics, has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Mineralys Therapeutics, regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Mineralys Therapeutics, stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Mineralys Therapeutics, stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Mineralys Therapeutics, stock over time.
Current vs Lagged Prices |
| Timeline |
Mineralys Therapeutics, Lagged Returns
When evaluating Mineralys Therapeutics,'s market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Mineralys Therapeutics, stock have on its future price. Mineralys Therapeutics, autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Mineralys Therapeutics, autocorrelation shows the relationship between Mineralys Therapeutics, stock current value and its past values and can show if there is a momentum factor associated with investing in Mineralys Therapeutics, Common.
Regressed Prices |
| Timeline |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Mineralys Stock Analysis
When running Mineralys Therapeutics,'s price analysis, check to measure Mineralys Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mineralys Therapeutics, is operating at the current time. Most of Mineralys Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Mineralys Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mineralys Therapeutics,'s price. Additionally, you may evaluate how the addition of Mineralys Therapeutics, to your portfolios can decrease your overall portfolio volatility.